99 completed, 31 terminated, 8 active not recruiting, 7 withdrawn. 81 Phase 1, 75 Phase 2, 14 Not applicable, 3 Phase 3, 2 Early Phase 1.
Follow Recurrent Grade 2 Follicular Lymphoma: new trials by email Literature Review of Recurrent Grade 2 Follicular Lymphoma trials Research Report on Recurrent Grade 2 Follicular Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Biopsy, Biospecimen Collection, Bone Marrow Aspiration - Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 1 | Recruiting | City of Hope Medical Center | 37 | 2025-08-25 | 2026-04-20 |
| Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma | Phase 2 | Suspended | City of Hope Medical Center | 33 | 2025-03-11 | 2026-01-21 |
| Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 41 | 2024-09-09 | 2026-09-22 |
| Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma Lenalidomide, Ublituximab, Umbralisib - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Phase 1 | Withdrawn | Yazeed Sawalha | 2022-09-30 | 2022-09-30 | |
| CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL CpG-STAT3 siRNA CAS3/SS3, Radiation Therapy - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Withdrawn | City of Hope Medical Center | 2021-07-27 | 2024-04-25 | |
| Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma Polatuzumab Vedotin, Rituximab, Rituximab and Hyaluronidase Human - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma | Phase 2 | Terminated | Academic and Community Cancer Research United | 3 | 2021-04-01 | 2024-09-19 |
| Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies Nivolumab - Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma | Phase 2 | Completed | University of Washington | 20 | 2020-06-05 | 2026-06-26 |
| Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma Carmustine, Cytarabine, Etoposide - Hematopoietic Cell Transplantation Recipient, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Completed | Ohio State University Comprehensive Cancer Center | 19 | 2018-09-10 | 2025-05-14 |
| Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22 anti-CD19/22-CAR vector-transduced T cells - Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 / Phase 2 | Unknown | Chinese PLA General Hospital | 30 | 2017-08-01 | 2019-04-17 |
| Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL. Laboratory Biomarker Analysis, Pembrolizumab, Vorinostat - Grade 3b Follicular Lymphoma, Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic HL | Phase 1 | Active not recruiting | City of Hope Medical Center | 52 | 2017-07-18 | 2026-08-21 |
| Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20 anti-CD19/20-CAR vector-transduced T cells - Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 / Phase 2 | Completed | Chinese PLA General Hospital | 100 | 2017-04-01 | 2020-09-02 |
| Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma Laboratory Biomarker Analysis, Lenalidomide, Nivolumab - Grade 3a Follicular Lymphoma, Recurrent Burkitt Lymphoma | Phase 1 / Phase 2 | Completed | David Bond, MD | 36 | 2017-02-14 | 2026-09-23 |
| Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma Blinatumomab, Lenalidomide - Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 35 | 2016-11-15 | 2025-11-26 |
| Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma rituximab, lenalidomide, romidepsin - B-cell Adult Acute Lymphoblastic Leukemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Phase 1 / Phase 2 | Withdrawn | Mayo Clinic | 2016-10-01 | 2016-08-11 | |
| Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma Anti-ICOS Monoclonal Antibody MEDI-570, Laboratory Biomarker Analysis, Pharmacological Study - Advanced Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 21 | 2016-09-13 | 2026-10-26 |
| Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma anti-CD19 CAR-T, Fludarabine, Cyclophosphamide - Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 / Phase 2 | Unknown | The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine | 20 | 2016-02-01 | 2017-03-16 |
| Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma Laboratory Biomarker Analysis, Lenalidomide, Pembrolizumab - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 53 | 2015-07-31 | 2026-10-22 |
| Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas Ibrutinib, Idelalisib, Laboratory Biomarker Analysis - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia | Phase 2 | Completed | Mayo Clinic | 65 | 2015-02-19 | 2026-06-24 |
| Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma carmustine, cytarabine, melphalan - Adult Nasal Type Extranodal NK/T-cell Lymphoma, AIDS-related Diffuse Large Cell Lymphoma | Not applicable | Withdrawn | Fred Hutchinson Cancer Center | 2015-02-01 | 2015-05-07 | |
| CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma 6,8-bis(benzylthio)octanoic acid, bendamustine hydrochloride, rituximab - B-cell Adult Acute Lymphoblastic Leukemia, B-cell Chronic Lymphocytic Leukemia | Phase 1 | Terminated | Wake Forest University Health Sciences | 1 | 2014-12-01 | 2018-07-02 |
Showing 20 of 152. Sign in to see all of them.
Lymphoma, Follicular (152) · Lymphoma, B-Cell, Marginal Zone (131) · Lymphoma, Mantle-Cell (128) · Leukemia, Lymphocytic, Chronic, B-Cell (125) · Lymphoma, Large B-Cell, Diffuse (118) · Lymphoma, Non-Hodgkin (105) · Waldenstrom Macroglobulinemia (100) · Burkitt Lymphoma (96) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (94) · Lymphoma, Large-Cell, Immunoblastic (88) · Mycosis Fungoides (72) · Hodgkin Disease (71) · Sezary Syndrome (71) · Lymphoma, T-Cell, Cutaneous (70) · Lymphoma, Large-Cell, Anaplastic (64)
Hemic and Lymphatic Diseases (152) · Immune System Diseases (152) · Immunoproliferative Disorders (152) · Lymphatic Diseases (152) · Lymphoma (152) · Lymphoproliferative Disorders (152) · Neoplasms by Histologic Type (152) · Neoplasms (151) · Hematologic Diseases (137) · Lymphoma, B-Cell (135) · Leukemia (129) · Leukemia, Lymphoid (129) · Disease Attributes (126) · Pathologic Processes (126) · Pathological Conditions, Signs and Symptoms (126)
Rituximab (33) · Peripheral Blood Stem Cell Transplantation (24) · fludarabine phosphate (23) · Whole-Body Irradiation (18) · Cyclophosphamide (17) · Mycophenolic Acid (17) · Cyclosporine (13) · Bortezomib (11) · Lenalidomide (11) · Etoposide (10) · Flow Cytometry (10) · Tacrolimus (10) · Filgrastim (9) · Granulocyte Colony-Stimulating Factor (9) · Vorinostat (8)
National Cancer Institute (NCI) (60) · Fred Hutchinson Cancer Center (26) · City of Hope Medical Center (12) · Mayo Clinic (7) · Case Comprehensive Cancer Center (6) · Roswell Park Cancer Institute (5) · Chinese PLA General Hospital (4) · University of Washington (3) · Kami Maddocks, MD (2) · M.D. Anderson Cancer Center (2) · Ohio State University Comprehensive Cancer Center (2) · Robert Lowsky (2) · Wake Forest University Health Sciences (2) · Academic and Community Cancer Research United (1) · Amir Mortazavi (1)
United States (142) · Italy (7) · Canada (5) · China (5) · Germany (5) · Denmark (1) · Singapore (1)
Ajay Gopal (7) · David Maloney (6) · Brenda Sandmaier (5) · Kami Maddocks, MD (3) · Paul Martin (3) · Ryotaro Nakamura (3) · Anas Younes (2) · Brenda Cooper (2) · George Chen (2) · John Gerecitano (2) · Leslie Popplewell (2) · Patricia LoRusso (2) · Philip McCarthy (2) · Ramesh Ramanathan (2) · Stephen Ansell (2)
PMID 32499241, PMID 34515338, PMID 27118452, PMID 18256325, PMID 19900571, PMID 20837940, PMID 21073974, PMID 21300924, PMID 21508413, PMID 21725056, PMID 22259028, PMID 22308288, PMID 23256542, PMID 24241210, PMID 24474568, PMID 24530971, PMID 25085357, PMID 25317870, PMID 25355819, PMID 25444722, PMID 26213141, PMID 26451310, PMID 26764356, PMID 26853648, PMID 26943915, PMID 28270022, PMID 28314788, PMID 28424162, PMID 28817727, PMID 29074501, PMID 29263894, PMID 29292843, PMID 29572391, PMID 29599530, PMID 30454872, PMID 30562587, PMID 31076448, PMID 31388792, PMID 31481800, PMID 31617432, PMID 31815579, PMID 32245502, PMID 32628342, PMID 33420905, PMID 33492438, PMID 34780125, PMID 35015819, PMID 36282798, PMID 36826995, PMID 37339586
P30CA015704 (14), P30CA015083 (9), P30CA033572 (7), U01CA076576 (7), U01CA062502 (6), U01CA062505 (6), P01CA018029 (5), U01CA062487 (5), U01CA062491 (5), U01CA099168 (5), P50CA107399 (4), N01CM17003 (3), N01CM62202 (3), P01CA044991 (3), P01CA078902 (3)